Virus Manufacturing

ABL has a long history of development and manufacturing of preclinical and clinical virus-based biologics. From 30 years of groundbreaking work with HIV to supporting the latest gene therapy technologies, ABL offers a comprehensive portfolio of services for the effective design, development, manufacturing and analytical testing of vaccine and virus vector products.

Interested in knowing more about our virus manufacturing services?

virus manufacturing,viral vectors for gene therapy,viral vectors gene therapy

As a leading CMO in virus manufacturing, ABL offers:

  • Upstream and Downstream Process Development
  • Master and Working Cell Banks
  • Master and Working Viral Banks
  • Adherent production in Roller Bottle, Cell Stacks / Factories, and HYPERstacks
  • Suspension production in Single-use Bioreactors ranging from 2L – 400L working volume.
  • Bulk Drug Substance (BDS) Scale-up and Engineering (non-GMP) runs
  • Bulk Drug Substance (BDS) GMP runs
  • Drug Product (DP) Filling
  • Analytical Development and Assay Qualification
  • In-process and Release QC testing
  • Stability Studies
  • CMC support
  • Comprehensive Program Management

ABL’s expertise in virus manufacturing includes:

  • Adenovirus
  • Adeno-associated virus (AAV)
  • Influenza
  • Poxviruses, i.e. Modified Vaccinia Ankara (MVA), Vaccinia
  • Retroviruses, i.e. HIV, Lentivirus
  • Rhabdovirus, i.e. Maraba virus (oncolytic virus), Vesicular stomatitis virus (VSV)
  • Virus-like particles (VLPs)
  • Lytic and non-lytic viruses
  • Enveloped and non-enveloped viruses